What’s new, what’s next and where to find us. This is your hub for our CRO lab announcements, insights and events—because in bioanalysis, momentum matters.
Veloxity Labs, a leading bioanalytical CRO specializing in LC-MS bioanalysis, today announced strong first quarter growth and continued expansion in 2026.
Our CEO, Shane Needham, PhD, was recently featured in The Analytical Scientist discussing the impact of GLP-1 receptor agonists and emerging peptide therapeutics.
Veloxity Labs has acquired the SCIEX ZenoTOF 8600 system, becoming the first bioanalytical CRO to bring this accurate-mass system online. The 8600 adds HRAM selectivity/sensitivity and expanded mass range for intact peptides/proteins—speeding method cycles for GLP-1 RAs and broader peptide programs while complementing our triple-quads. Delivery is expected this year; install/qualification begins January 2026.
Read the full release.
We’ve partnered with Carolina Martinez — a record-setting sprinter, Bradley University standout and cancer survivor — in a powerful new NIL collaboration.
We’re proud to support Silo Pharma in advancing SPC-15, a novel intranasal therapy for PTSD. We're providing GLP bioanalysis for their IND-enabling safety study.
Veloxity Labs will be attending the upcoming PBSS event focused on small molecule preclinical development and IND-enabling strategies. Hope to see you there!
Veloxity Labs will be presenting at the 2026 AAPS National Biotechnology Conference, a leading forum for scientific exchange in bioanalysis, pharmacokinetics and drug development.
We’ll be attending the 2026 Great Lakes Drug Metabolism Discussion Group (GLDMDG) Annual Meeting, which brings together scientists focused on drug metabolism, pharmacokinetics (PK/DMPK) and bioanalytical strategy.
Veloxity will be attending and sponsoring lunch at the PBSS Vendor Scientific Highlights Symposium to connect with peers working on large-molecule programs.
